Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pilheu, J.
Right arrow Articles by Koch, O
Right arrow Search for Related Content
PubMed
Right arrow Articles by Pilheu, J.
Right arrow Articles by Koch, O

Chest, Vol 80, 720-722, Copyright © 1981 by American College of Chest Physicians

ARTICLES

Liver alterations in antituberculosis regimens containing pyrazinamide

JA Pilheu, MC De Salvo and O Koch

A group of alcoholic tuberculous patients was given a pyrazinamide- containing regimen, and the liver was studied on admission and after two months of intensive treatment with IRSZ. Alterations in liver histology and in liver function tests found on admission improved or disappeared after two months' chemotherapy. A control group, give IRSE, showed similar results. A third group of nonalcoholic patients was given Z alone for 15 days, and liver tolerance was also excellent. These data support the conclusion that tuberculous alcoholic patients, in the absence of significant and persistent hepatic dysfunction, can be given Z-containing regimens. In all cases, a careful monitoring of hepatic function, with monthly SGPT and bilirubin determinations, is recommended.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1981 by the American College of Chest Physicians.